Man Group
ABUS icon

Man Group’s Arbutus Biopharma ABUS Stock Holding History

Man Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-120,821
Closed -$581K – 2368
2025
Q4 		$581K Buy
120,821
+41,447
+52% +$186K ﹤0.01% 1850
2025
Q3 		$360K Buy
79,374
+40,377
+104% +$148K ﹤0.01% 1950
2025
Q2 		$121K Buy
+38,997
New +$129K ﹤0.01% 2113
2023
Q3 		– Sell
-24,500
Closed -$56.4K – 1898
2023
Q2 		$56.4K Buy
+24,500
New +$63.8K ﹤0.01% 1910
2023
Q1 		– Sell
-44,900
Closed -$105K – 2055
2022
Q4 		$105K Sell
44,900
-42,346
-49% -$101K ﹤0.01% 1904
2022
Q3 		$167K Buy
+87,246
New +$205K ﹤0.01% 1796

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Man Group's ABUS Position: Q1 2026 in Review

Man Group sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 120,821 shares — an estimated $581K sold.

Man Group first reported a position in ABUS in Q3 2022 and held it in 6 quarters. The position peaked at $581K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Man Group reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Man Group sold 120,821 Arbutus Biopharma shares in Q1 2026, an estimated $581K.
  • Man Group first reported a position in Arbutus Biopharma in Q3 2022 and held it in 6 quarters.
  • Man Group's Arbutus Biopharma position peaked at $581K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.